Harmony Biosciences
HRMY
272 hedge funds and large institutions have $1.67B invested in Harmony Biosciences in 2025 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 100 increasing their positions, 88 reducing their positions, and 16 closing their positions.
215% more call options, than puts
Call options by funds: $4.95M | Put options by funds: $1.57M
156% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 16
14% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 88
10% more funds holding
Funds holding: 247 → 272 (+25)
4.85% less ownership
Funds ownership: 92.5% → 87.66% (-4.8%)
8% less capital invested
Capital invested by funds: $1.82B → $1.67B (-$148M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NVCHI
New Vernon Capital Holdings II
Morristown,
New Jersey
|
+$17M |
| 2 |
Renaissance Technologies
New York
|
+$9.74M |
| 3 |
JP Morgan Chase
New York
|
+$8.92M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
+$8.56M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$7.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$63.9M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$49.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$18.1M |
| 4 |
BlackRock
New York
|
-$16.4M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$14.9M |
HRMY Hedge Fund Activity: Q1 2025 in Review
272 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q1 2025, worth a combined $1.67B — down 8.2% from $1.82B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new HRMY positions and 16 closed out — a net gain of 25 holders — while 100 added to existing stakes and 88 trimmed.
The largest buyer was New Vernon Capital Holdings II, adding an estimated $17M. The largest seller was Pacer Advisors, cutting an estimated $63.9M.
- 272 institutional investors held Harmony Biosciences (HRMY) as of Q1 2025, up from 247 in Q4 2024.
- Funds reported $1.67B of Harmony Biosciences stock for Q1 2025, down 8.2% quarter-over-quarter.
- 41 funds opened new Harmony Biosciences positions in Q1 2025 and 16 closed out, a net change of +25 holders.
- The largest Harmony Biosciences buyer in Q1 2025 was New Vernon Capital Holdings II, an estimated $17M added.
- The largest Harmony Biosciences seller in Q1 2025 was Pacer Advisors, an estimated $63.9M sold.
Based on aggregated 13F filings for Q1 2025.